-
May 17, 2022 Apotex Launches Affordable Generic Option to Treat Relapsing Remitting Multiple Sclerosis
-
Apr 12, 2022 Apotex Corp. Launches Generic of Abraxane® in the United States
-
Feb 2, 2021 Apotex Corp. Issues Voluntary Nationwide Recall of Enoxaparin Sodium Injection, USP Due to Mislabeling of Syringe Barrel Measurement Markings
-
May 26, 2020 APOTEX CORP. DONATES CRITICAL MEDICINES IN THE FIGHT AGAINST COVID-19
-
May 26, 2020 Canada’s largest pharmaceutical manufacturer donates thousands of bottles of hand sanitizer to hospitals across Quebec
-
May 25, 2020 Toronto Company Launches Hiring Blitz During COVID-19
-
Apr 21, 2020 Canada’s Apotex Donates Two Million Dosages of Hydroxychloroquine to the Public Health Agency of Canada
-
Apr 17, 2020 Canada’s Apotex Donates Critical N95 Masks to Support Frontline Healthcare Workers
-
Apr 13, 2020 Canada’s Largest Pharmaceutical Company Produces Hand Sanitizer to Support the Fight Against COVID-19
-
Mar 23, 2020 APOTEX DONATES HYDROXYCHLOROQUINE FOR A CLINICAL STUDY TO PREVENT INFECTION FROM COVID-19 WITH FRONT LINE HEALTH CARE WORKERS
-
Mar 5, 2020 Apotex Statement: Drug Supply and COVID-19
-
Sep 20, 2018 ACCC announces clearance of the merger of Arrow Pharmaceuticals & Apotex Australia & NZ merger
-
Jul 14, 2018 Apotex Focuses on High Growth Markets with Sale of European Generics Business
-
Jun 1, 2018 Apotex Builds Momentum in Canada's Biosimilar Market After World's First Approval
-
May 9, 2018 Apotex Announces Proposed Merger of AUS & NZ Operations
-
Jun 12, 2017 Apobiologix Applauds Supreme Court Decision in Sandoz Biosimilar Case
-
Jun 8, 2017 Canadian Scientists Honored for Role in Breakthrough Drug
-
Apr 28, 2017 University of Saskatchewan, Apotex renew partnership with $1.6M donation to the College of Pharmacy and Nutrition
-
Mar 8, 2017 Apotex Announces $184 Million Investment to Grow U.S. Manufacturing Presence; Expansion Plan Comprises Company's Largest Investment in the United States
-
Mar 31, 2016 Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 9, 2026
Apotex to announce second quarter fiscal 2027 financial results and host conference call on Nov. 12, 2026
TORONTO, Oct. 8, 2026 /CNW/ -- Apotex Health Corp.("Apotex") (TSX: APTX) today announced that it will issue a press release with its second quarter Fiscal 2027 financial results on Thursday, November 12, 2026, at approximately 6:00 a.m. ET. Apotex will host a conference call and live webcast to discuss the results at 8:00a.m. ET.
-
Oct 5, 2026
Apotex Health Corp. announces closing of $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, October 5, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today the closing of the previously announced offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Offering was made through a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.
-
Sep 29, 2026
Apotex Health Corp. announces $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, September 28, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today that it has priced a private placement offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Notes are being offered on an agency basis by a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.